Related Experiment Video
Updated: Apr 30, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin in prostate cancer: a context-dependent antitumour strategy driven by metabolic vulnerability and
Lingling Yan1,2, Dan Chen1,2, Tong Wu1
1Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
Abstract:
Prostate cancer (PCa) is one of the most common malignant tumours in men and imposes a significant disease burden worldwide. Existing treatments have limitations such as drug resistance, and drug repurposing provides a new direction for drug management. Among the drugs explored, metformin has demonstrated certain preventive potential. Epidemiological evidence suggests that long-term use of metformin may be associated with reduced PCa incidence. This potential benefit is particularly evident in Asian and European populations. However, existing studies still exhibit heterogeneity, publication bias, and stage-specific variability. Its clinical efficacy varies by disease stage and individual patient characteristics: although it may reduce disease-specific mortality, evidence for consistent survival benefits remains limited and inconsistent. Notably, metformin possesses a favourable and controllable safety profile. Mechanistically, metformin exerts its antitumour effects through a coordinated network of metabolic and signalling pathways rather than a single dominant mechanism. In many prostate cancer contexts, inhibition of mitochondrial complex I likely represents a primary upstream event, leading to bioenergetic stress. This metabolic perturbation subsequently activates AMP-activated protein kinase (AMPK), suppresses mTOR signalling, and modulates androgen receptor (AR)-associated pathways. In parallel, metformin induces oxidative stress remodelling by increasing reactive oxygen species and disrupting redox homeostasis, which further contributes to tumour growth inhibition. Clinically, metformin does not yet show consistent survival benefits across unselected prostate cancer populations, but it may have potential value in specific disease stages and metabolically defined patient subgroups.
Insights
Metformin may reduce prostate cancer (PCa) incidence, particularly in Asian and European men, through metabolic pathway modulation. While not consistently improving survival across all patients, its safety and potential in specific subgroups warrant further investigation.
Area of Science:
- Oncology
- Pharmacology
- Metabolic pathways
Background:
- Prostate cancer (PCa) presents a significant global health challenge with existing treatments facing drug resistance.
- Drug repurposing, specifically exploring metformin, offers a promising avenue for novel prostate cancer management strategies.
- Epidemiological data suggests a potential link between long-term metformin use and reduced PCa incidence, especially in specific populations.
Purpose of the Study:
- To evaluate the potential preventive and therapeutic role of metformin in prostate cancer (PCa).
- To analyze the mechanisms underlying metformin's antitumour effects in PCa.
- To assess the clinical efficacy and safety profile of metformin for prostate cancer management.
Main Methods:
- Review of epidemiological studies and clinical trials investigating metformin's effect on PCa incidence and outcomes.
- Analysis of preclinical data elucidating metformin's molecular mechanisms of action, including metabolic and signaling pathway modulation.
- Assessment of metformin's safety profile and potential for drug repurposing in PCa treatment.
Main Results:
- Metformin use is associated with reduced PCa incidence in some populations, though studies show heterogeneity and variability.
- Mechanistically, metformin inhibits mitochondrial complex I, activating AMPK, suppressing mTOR, and modulating androgen receptor pathways, alongside inducing oxidative stress.
- Metformin demonstrates a favorable safety profile but lacks consistent survival benefits in unselected PCa populations.
Conclusions:
- Metformin shows potential for prostate cancer prevention and may offer therapeutic benefits in specific patient subgroups and disease stages.
- Its complex mechanism involving metabolic and signaling pathway disruption contributes to antitumour effects.
- Further research is needed to define the precise role of metformin in personalized prostate cancer therapy.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...